[CPHD] CEPHEID

Overview

Type of security: Stock

Sector: Capital Goods

Industry: Biotechnology: Laboratory Analytical Instruments

Market Capitalization: 2.39 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 52.95 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart CPHD

Refresh chart

Strongest Trends Summary For CPHD

CPHD is in the long-term up 1184% in 26 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical and non-clinical markets; and for application in legacy non-clinical market. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection; and SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also provides GeneXpert Infinity System for high volume testing. The company offers GeneXpert system for testing in the areas of healthcare associated infections, critical infectious disease, sexual hea

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding72.89 M EPS-0.69 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 13.85% Sales Growth - Q/Q0.85% P/E-76.74
P/E To EPS Growth P/S4.82 P/BV6.35 Price/Cash Per Share7.7
Price/Free Cash Flow-63.25 ROA-4.91% ROE-10.61% ROI-5.9%
Current Ratio4.2 Quick Ratio3.14 Long Term Debt/Equity0.66 Debt Ratio0.35
Gross Margin52.12% Operating Margin-4.67% Net Profit Margin-8.05% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities20.57 M Cash From Investing Activities-13.18 M Cash From Operating Activities7.92 M Gross Profit63.1 M
Net Profit-16.73 M Operating Profit-10.75 M Total Assets823.88 M Total Current Assets548.35 M
Total Current Liabilities141.79 M Total Debt282.98 M Total Liabilities449.39 M Total Revenue132.47 M
Technical Data
High 52 week52.95 Low 52 week25.64 Last close52.95 Last change0%
RSI58.93 Average true range3.86 Beta0.22 Volume
Simple moving average 20 days0.14% Simple moving average 50 days2.59% Simple moving average 200 days44.93%
Performance Data
Performance Week0% Performance Month0.38% Performance Quart48.15% Performance Half105.23%
Performance Year48.03% Performance Year-to-date0% Volatility daily0.12% Volatility weekly0.27%
Volatility monthly0.56% Volatility yearly1.93% Relative Volume0% Average Volume2.11 M
New High New Low

News

2017-02-14 05:00:11 | These drug and medical device companies made the most payments to L.A. hospitals

2017-01-31 12:15:59 | Mario Gabelli Comments on Cepheid

2017-01-31 12:02:57 | Mario Gabelli's ABC Fund Merger and Arbitrage 'The Deal Fund' 4th Quarter Shareholder Commentary

2017-01-17 16:36:05 | Behind Danaher’s 4Q16 Revenue Estimates

2016-12-05 10:44:21 | Here is What Hedge Funds Think About Clear Channel Outdoor Holdings, Inc. CCO

2016-12-05 10:28:45 | 5 Healthcare Stocks Billionaires Are Buying

2016-12-03 17:30:35 | Is Chemed Corporation CHE Going to Burn These Hedge Funds?

2016-11-30 13:32:39 | Cepheid CPHD: What Smart Money Thinks about This Stock?

2016-11-15 13:04:11 | CEPHEID Financials

2016-11-07 17:36:34 | CEPHEID Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or

2016-11-03 16:28:32 | CEPHEID Files SEC form 10-Q, Quarterly Report

2016-10-28 16:51:33 | CEPHEID Files SEC form 8-K, Change in Directors or Principal Officers

2016-10-27 08:26:08 | 30 Minute Or Less Molecular Flu/RSV Test Now Available Outside The US

2016-10-27 08:00:00 | 30 Minute Or Less Molecular Flu/RSV Test Now Available Outside The US

2016-10-24 08:21:04 | Cepheid Announces Receipt of Required Regulatory Clearances in Proposed Acquisition by Danaher Corporation

2016-10-24 08:08:01 | CEPHEID Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2016-10-24 08:00:00 | Cepheid Announces Receipt of Required Regulatory Clearances in Proposed Acquisition by Danaher Corporation

2016-10-24 07:47:11 | Medical Product Oct 25 Earnings Roster: BAX, RMD, CPHD, EW

2016-10-20 10:33:02 | Danaher DHR Q3 Earnings Top Estimates, Revenues Up Y/Y

2016-10-17 10:32:02 | What's in Store for Cepheid CPHD this Earnings Season?

2016-10-17 09:52:01 | Medical Stocks Q3 Earnings on Oct 18: JNJ, UNH, CPHD, ISRG

2016-10-14 09:33:01 | Exactech Enters Foot & Ankle Space with Vantage System

2016-10-13 08:54:12 | Exactech: Surgery Technology Studies Encourage, Stock Up

2016-10-12 08:21:12 | Patterson Companies & Heartland Dental Form Partnership

2016-10-11 10:06:16 | Why Danaher Is Relatively Immune from Growth Concerns in China

2016-10-10 09:20:01 | Cepheid: Commercial Launch of Xpert Bladder Cancer Monitor

2016-10-07 18:09:35 | Columbia Wanger Sold 2 Stakes in September

2016-10-07 07:36:11 | Baxter BAX: Portfolio Strong, Cyclophosphamide Sales Low

2016-10-05 16:28:04 | New Bladder Cancer Test Could Reduce Number Of Invasive Procedures Required For Recurrence Monitoring

2016-10-05 16:05:00 | New Bladder Cancer Test Could Reduce Number Of Invasive Procedures Required For Recurrence Monitoring

2016-09-26 13:34:05 | Proxy Statement Shows Danaher Faced Competition In Bid To Buy Cepheid

2016-09-20 12:56:40 | 5 Notable NASDAQ Names Notched 52-Week Highs on Monday

2016-09-16 12:58:16 | Why GenMark Diagnostics, Inc. Is Soaring Today

2016-09-16 09:21:01 | Cepheid Announces Expansion of Molecular C. Difficile Product

2016-09-15 16:18:06 | Cepheid Announces Expansion Of The Most Comprehensive Molecular C. Difficile Product Portfolio On The Market

2016-09-15 16:05:00 | Cepheid Announces Expansion Of The Most Comprehensive Molecular C. Difficile Product Portfolio On The Market

2016-09-14 10:10:02 | Cepheid's CPHD Shares March Higher, Can It Continue?

2016-09-13 15:18:00 | Lifshitz & Miller Law Firm Announces Investigation of AECOM, American Farmland Company, Centene Corp., Cepheid, Cray Inc., Echo Global Logistics, Inc., Ocular Therapeutix, Inc., and Pure Storage, Inc.

2016-09-12 16:11:00 | INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Cepheid And Encourages Shareholders To Contact The Firm For Additional Information

2016-09-12 10:21:00 | Cepheid CPHD Stock Downgraded to 'Neutral' at Baird

2016-09-10 00:01:00 | [$$] Charting the Market

2016-09-09 17:17:00 | CEPHEID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Cepheid CPHD Over the Proposed Sale of the Company to Danaher Corporation

2016-09-09 15:23:00 | Cepheid Acquisition May Not Be in the Best Interests of CPHD Shareholders

2016-09-08 16:19:03 | Cepheid Targets Development of a Point of Care HIV Viral Load Test From a Few Drops of Blood

2016-09-08 16:05:00 | Cepheid Targets Development of a Point of Care HIV Viral Load Test From a Few Drops of Blood

2016-09-08 10:55:06 | Cepheid – Value Analysis NASDAQ:CPHD : September 8, 2016

2016-09-08 08:07:12 | Will Cepheid's CPHD Buyout by Danaher be a Strategic Fit?

2016-09-07 18:04:05 | How Cepheid Fits Strategically into DHR’s Portfolio

2016-09-07 17:37:00 | Harwood Feffer LLP Announces Investigation of Cepheid

2016-09-07 17:17:00 | SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Cepheid And Encourages Investors To Contact The Firm For Additional Information